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1. Introduction
The number of patients with malignancies in the world con-
tinues to increase. It is estimated that 10 million new cases are
diagnosed every year and that 2 million people are either
receiving treatment or are living with their disease. The last
decades have seen a rapid growth in medical technology and
in the advances of fundamental knowledge of cancer cell
biology with impact on genetics, screening, early diagnosis,
staging, and overall treatment of cancer.
These developments have also led to a more coordinated,
multidisciplinary approach to the management of the individ-
ual malignancy and the need to establish formal training based
on a set of guidelines or a curriculum in the various major
specialities such as surgery, radiotherapy, and medical
oncology.
The foundation for the establishment of medical oncology
as a speciality was created in 1965 when the American
Society of Clinical Oncology (ASCO) was founded. A uni-
form system of training in medical oncology in the United
States was formulated by the American Board of Internal
Medicine in 1989 [1]. In 1997, ASCO published a training
resource document for development of a curriculum in medi-
cal oncology [2].
The European Society for Medical Oncology (ESMO)
started an examination in medical oncology in 1989 for phys-
icians actively working in the field. To guarantee maintenance
and update of the knowledge, skills, and attitudes of these
physicians, which is essential to the provision of excellent
care, the program of continued education of medical oncology,
the ESMO-Medical Oncologist’s Recertification Approval
program, was introduced in 1994 [3].
The main objective of these certification systems is to
improve the quality of patient treatment and care, to set
standards of clinical competence for the practice of medical
oncology, and encourage a continued scholarship for
professional excellence over a lifetime of practice.
In 1998, a standard program of certification and training for
medical oncology was published in accordance with the
requirements imposed by the Union Europe´enne des Me´dicins
Specialistes for recognition of medical oncology as an inde-
pendent discipline. At present, medical oncology is a recog-
nized specialty in 14 countries in Europe.
Also, in other areas of the world, teaching and training
programs in medical oncology have been developed.
With the increasing internationalization of health care,
exchange of specialists, and rapid flow of information over
borders, it is time to develop a set of common guidelines with
a global perspective for the clinical training required for phys-
icians to qualify as medical oncologists. Thus, a joint
ESMO/ASCO Task Force has proposed this first Global Core
Curriculum in Medical Oncology.
2. Standard requirements for training in
medical oncology
The standard requirements are a total training period of
6 years, beginning with training in internal medicine for at
least 2 years, followed by a training program in medical
oncology for 3 to 4 years.
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The 3- to 4-year training program in medical oncology
must include a minimum of 2 years full-time clinical training
in the diagnosis and management of a broad spectrum of
neoplastic diseases.
Full-time clinical training means that at least 80% of the
trainee’s professional time and effort during a standard work-
ing week is dedicated to clinical activities (patient care or
education). These may include the primary care of cancer
patients, supervision of cancer patients on the general medical
service or in designated medical oncology in-patient units,
oncologic consultations and consultation rounds, oncology
ambulatory care, scheduled clinical conferences, performance
of procedures on patients, review of imaging, pathology, and
other diagnostic materials, other direct patient care, attending
national and international scientific meetings, and reading
relevant literature.
Clinical activities may also include research involving
patient contact, care, and treatment. Research experience for
1 or more years, including international training, is strongly
recommended, especially for the oncologists who want an
academic career.
3. Special requirements
3.1 Program leader
The medical oncology program leader must be qualified to
supervise and educate trainees in medical oncology. Thus, the
leader must either be certified in medical oncology or possess
equivalent qualifications. The leader will have a major com-
mitment to the training program and related activities, and
must be based at the primary training site of the medical
oncology program.
The trainee will maintain a record of training. The program
leader will countersign it, as appropriate, to confirm the satis-
factory fulfilment of the required training experience and the
acquisition of the competencies that are cumulated in the
speciality curriculum. It will remain the property of the trainee
and must be signed at the annual assessments. The assessment
of the trainee will be based on the standard format of annual
reviews.
3.2 Faculty
3.2.1 Faculty members
The medical oncology program faculty must include a mini-
mum of three full-time qualified teaching faculty members,
including the program leader.
All the faculty members must be certified in medical onco-
logy or possess equivalent qualifications, and each of them
must devote substantial time (at least 10 hours per week) to
teaching, research, administration, and/or the critical evalu-
ation of the performance, progress, and competence of the
trainees.
3.2.2 Faculty standards
The teaching staff must demonstrate an interest in teaching,
and set an example for trainees by documented engagement in
the following pursuits: actively sharing in a medical oncology
clinical practice; continuing his/her own medical education;
active membership in regional, national and international
scientific societies; active participation in research; and pres-
entation and publication of scientific studies.
3.3 Educational program
The educational program in medical oncology must be orga-
nized to provide training and experience at a level high
enough for the trainee to acquire the competency of a special-
ist in the field. The program must emphasize scholarship,
self-instruction, development of critical analysis of clinical
problems, and the ability to make appropriate decisions.
Appropriate supervision of the trainees must be provided for
the duration of their educational experience.
The following principles require special emphasis.
3.3.1 Educational environment
Medical oncology training programs must provide an intellec-
tual environment for acquisition of the knowledge, skills,
clinical judgement, and attitudes essential to the practice of
medical oncology. This objective can only be achieved when
appropriate resources and facilities are available. Service
commitments must not compromise the achievement of
educational goals and objectives.
3.3.2 Professionalism—ethics
Professionalism must be fostered during medical oncology
training. In addition to mastering the comprehensive clinical
and technical skills of the consultant medical oncologist, trai-
nees are expected to maintain the values of professionalism.
These values include placing the needs of one’s patient ahead
of one’s self-interest, being responsive to the needs of society,
and maintaining a commitment to scholarship and high
standards of related research. Trainees, therefore, should be
encouraged to participate in professional organizations, com-
munity programs, and institutional committees.
3.3.3 Responsibility
Lines of responsibility must be clearly delineated for the
trainees in medical oncology.
3.3.4 Institutional requirements
3.3.4.1 Clinical setting
The clinical setting must include opportunities to observe and
manage patients with a wide variety of neoplastic diseases on
an in-patient and out-patient basis. The trainee must be given
the opportunity to assume the continuing responsibility for
both acute and chronically ill patients in order to learn the
natural history of cancer, the extent of the effectiveness of the
various therapeutic programs, and how to impart information
to the patient, including bad news.
3.3.4.2 Hospital facilities
Modern in-patient, ambulatory care, and laboratory facilities
necessary for the overall educational program must be
1605
available and functioning. Specifically, at the primary site,
there must be adequate pathology services, modern diagnostic
radiology services, resources for nuclear medicine imaging,
blood banking and blood therapy facilities, and facilities for
clinical pharmacology and tumor immunology. A general sur-
gical service and its support must be available, in addition to
access to radiation therapy. The program must also include
attendance at a multidisciplinary tumor conference, and clini-
cal cancer protocol studies applied according to the guidelines
for good clinical practice.
3.3.5 Update of skills and knowledge
Having obtained certification in medical oncology, the special-
ist is expected to update the acquired skills and knowledge by
participating in Continuing Medical Education programs such
as courses, symposia or self-learning processes on a regular
basis.
3.3.6 Perception of other specialities
It is also essential to have the support of oncology nursing,
pharmacy, rehabilitation medicine, palliative care medicine,
and dietetic and psychosocial services so that the trainee can
perceive the role of other specialities in the total care of the
cancer patient.
3.3.7 Facilities
It is the responsibility of the teaching institute to oversee that
these facilities are available before a graduate medical
education program is initiated.
4. Competency comprising curriculum
The following curriculum should be considered as the edu-
cational framework for the training of physicians in medical
oncology.
4.1 Basic scientific principles
As a foundation for treating malignant disease, the trainee
should understand the biology of cancer, principles of therapy,
and proper conduct and interpretation of clinical research.
4.1.1 Cancer biology
Trainees should know the biology of normal cells and
the basic processes of carcinogenesis. They should have an
in-depth understanding of gene structure, organization,
expression, and regulation. A fundamental understanding of
the cell cycle, its control by oncogenesis, and its interaction
with therapy is important. They should understand tumor cell
kinetics, proliferation, and programmed cell death, and the
balance between cell death and cell proliferation. Trainees
should be familiar with molecular techniques, such as poly-
merase chain reaction, chromosomal analyses, and other tech-
niques of molecular and tumor cell biology.
4.1.2 Tumor immunology
The trainee should have basic knowledge of the cellular and
humoral components of the immune system and the regulatory
action of cytokines on the immune system. They should
understand the inter-relationship between tumor and host
immune systems, including tumor antigenicity, immune-
mediated antitumor cytotoxicity, and the direct effect of cyto-
kines on tumors.
4.1.3 Etiology, epidemiology, screening, and prevention
Trainees should have an understanding of the etiology of gen-
etic and environmental factors in oncogenesis. They should
have a basic knowledge in epidemiologic factors and descrip-
tors of disease. Trainees should understand the basic principles
of screening and risk assessment. They should know the sensi-
tivity and specificity of the test employed and the cost–benefit
ratio. They should know the situations in which screening has
a well-defined role and the situations in which the role of
screening is unclear or not defined. They should be aware of
the principles and indications for genetic screening and coun-
selling. They should know the value of prevention in cancer
development and what primary, secondary, and tertiary
preventive measures may be taken to prevent cancer
development.
4.1.4 Clinical research including statistics
Trainees must be provided an education in the design and con-
duct of clinical trials. They must have an exposure to the
development and conduct of these trials through international
cooperative groups or in-house protocols. That instruction
should include the following: clinical trial design, phase I–II–
III trials; review of the ethical, regulatory, and legal issues
involved in study design; criteria for defining response to
therapy; tools used to assess quality of life; basics of statistics,
including statistical methods, requirements for patient numbers
in designing studies, and proper interpretation of data; toxicity
assessment and grading; role and functioning of the insti-
tutional review board and ethical committees; experience
obtaining informed consent from patients; government regulat-
ory mechanisms of surveillance; instruction in grant writing
and information about mechanisms of support for clinical
research; cost of therapy and the cost-effectiveness of therapy;
instruction in preparing abstracts, oral and visual presenta-
tions, and writing articles; and they should be able to critically
evaluate the scientific value of published articles and their
influence on daily clinical practice.
4.2 Basic principles in the management and treatment
of malignant diseases
The management of malignant diseases requires the expertise
of many different medical subspecialities, and the majority of
patients with malignant diseases are best managed in a multi-
disciplinary approach with integration of the various subspeci-
alities because of increasing complexity of modern treatment.
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The trainee should recognize the contributions of each of
these subspecialties in making the diagnosis, assessing disease
stage, and treating the underlying disease and its compli-
cations. The trainees should interact with each of these disci-
plines in order to gain an appreciation of the benefits and
limitations of each modality. Participation of the trainees in
interdisciplinary meetings is encouraged. The trainees should
be capable of assessing the patient’s comorbid medical con-
ditions, that may affect the toxicity and efficacy of treatment,
in order to formulate a treatment plan and be aware of
the special conditions that influence the treatment of the grow-
ing population of elderly patients with malignant disorders.
4.2.1 Pathology/laboratory medicine/molecular biology
The trainee should know that the definite diagnosis of cancer
is based on a cytology or biopsy. The trainees should have the
opportunity to review biopsy material and surgical specimens
with a pathologist. They should appreciate the role of the
pathologist in confirming the diagnosis of cancer and in deter-
mining the severity and extent of disease. Trainees should be
familiar with newer pathologic techniques and the contribution
of these techniques to the staging and management of patients
with cancer. Trainees should know what laboratory testing is
appropriate in the staging and follow-up of patients. They
should appreciate the utility of markers (serum tumor markers,
cell membrane markers, DNA markers) and recognize their
limitations.
4.2.2 Staging procedures
Trainees should know the tumor–node–metastasis staging
system and how to stage a cancer patient. They should know
the indications for clinical, radiographic, and nuclear medicine
imaging procedures in the diagnosis, staging, and follow-up of
patients with malignant diseases. They should learn to assess
response to treatment using these tests.
4.2.3 Therapy
4.2.3.1 Surgery
By interacting with surgeons, the trainee should develop an
understanding of the indications and contraindications of sur-
gery. They should become knowledgeable about the role of
surgery in the staging, cure, and palliation of patients with
malignant diseases. The trainee should become familiar with
the indications of organ preservation and the sequencing of
surgery with other treatment modalities. They should recog-
nize the risks and benefits of surgery as a definitive treatment
and as an adjunct to radiotherapy and/or anticancer agents. In
addition, the trainees should be aware of postoperative
complications.
4.2.3.2 Radiation oncology
The trainee should be familiar with the principles of radiation
biology and the indications of radiation therapy as a curative
and palliative modality. They should be familiar with the prin-
ciples of treatment planning and dosimetry. The trainee should
appreciate when radiation therapy should be sequenced with
surgery and/or anticancer agents. They should recognize both
the acute and late effects of radiation therapy.
4.2.3.3 Anticancer agents
Trainees should be familiar with the indications and goals of
useful treatment with anticancer agents in primary and recur-
rent malignant disorders. They should know the usefulness of
these agents in the neo-adjuvant, concomitant, and adjuvant
setting. They should know the indications of anticancer agents
as a radiation sensitizer. They should know the importance of
dosing and treatment delay of specific anticancer agents. They
should be able to assess a patient’s comorbid medical con-
ditions in order to determine the risk/benefit ratio of treatment
with anticancer agents for that individual patient. Knowledge
of the pharmacokinetics, pharmacogenomics, and pharma-
cology of the various agents should be obtained. Trainees
should know the toxicity profile of each anticancer agent,
including long-term hazards, how to adapt the dose and treat-
ment schedule according to the individual patient in case of
organ dysfunction, and how to handle these complications.
4.2.3.4 Biologic therapy
Trainees should be familiar with the activities and indications
for biologic therapy, including cytokines and hematopoietic
growth factors. Knowledge should include the spectrum of
specific side effects and their management and therapeutic
combinations with chemotherapy. The trainee should also be
familiar with basic concepts of targeted molecular therapies,
such as monoclonal antibodies, tumor vaccines, cellular
therapy, and gene-directed therapy.
4.2.3.5 Supportive and palliative measurements
Trainees should know what supportive therapy during antican-
cer therapy is, and should be able to use supportive therapy.
They should know the indications of the different supportive
treatments and their limitations and side-effects. Trainees
should know what palliative therapy is and should be able to
determine when palliative care is indicated. They should know
what palliative care and end-of-life care is and how to
implement this in their clinical practice. They should know
that palliative care is an integrated part of medical oncology,
and that is has a multidisciplinary dimension.
4.2.3.5.1 Supportive measures:
4.2.3.5.1.1 Nausea and vomiting. The trainee should know the
various etiologies of nausea and vomiting in patients with
malignancies, and recognize the mechanism of action and
pharmacology of anti-emetic agents and how to use them in
daily clinical practice
4.2.3.5.1.2 Infections and neutropenia. The trainee should
know the principles of diagnosis and management of infec-
tions and neutropenic fever in all types of cancer patients.
They should know how to treat and prevent infections. They
should know the indications of the use of hematologic growth
factors.
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4.2.3.5.1.3 Anemia. The trainee should know the indications
and complications of red blood cell transfusions. They should
be aware of the options regarding preparation and adminis-
tration of these products. They should know the appropriate
use of erythropoietin.
4.2.3.5.1.4 Thrombocytopenia. The trainee should know the
indications and complications of platelet transfusions. They
should be aware of the options regarding preparation and
administration of these products.
4.2.3.5.1.5 Marrow and peripheral-blood progenitor cells.
Trainees should be familiar with the methods for marrow
and peripheral-blood progenitor cells procurement and cryo-
preservation.
4.2.3.5.1.6 Organ protection. The trainee should be familiar
with the use of organ-protective measurements and treatments.
They should know the indications and side-effects of different
organ-protective agents. They should know the techniques of
gonad preservation to ensure the fertility of the patient (cryo-
preservation techniques).
4.2.3.5.1.7 Mucositis. The trainee should be able to distinguish
mucositis, which is infectious, from that caused by anticancer
agents. They should be aware of the need for pain medication
and topical anesthetics as palliation.
4.2.3.5.1.8 Malignant effusions. The trainee should know the
signs, symptoms, and treatments and their indication of ascites
and pleural and pericardial effusions. They should be able to
treat effusions by paracenthesis
4.2.3.5.1.9 Extravasation. Trainees should know that preven-
tion is the most important factor in extravasation. They should
be able to diagnose and treat extravasation.
4.2.3.5.1.10 Oncologic emergencies. Trainees should recog-
nize the clinical presentations that require immediate interven-
tion (e.g., spinal cord compression, pericardial tamponade).
For patients in whom a diagnosis of cancer is suspected, the
trainee should know the proper approach for obtaining a tissue
diagnosis. They should know what therapy is required in the
acute and chronic setting.
4.2.3.5.1.11 Paraneoplastic syndromes. Trainees should recog-
nize the “remote effects” of malignancy, potentially mani-
fested in every organ system. They should recognize which
malignancies are most commonly associated with the individ-
ual syndromes. Trainees should know the appropriate manage-
ment of each syndrome.
4.2.3.5.1.12 Nutritional support. Trainees should know the
indications for and complications of enteral and parenteral
support.
4.2.3.5.2 Palliative care and end-of-life care:
4.2.3.5.2.1 Pain. Trainees should be adept in their ability to
assess location and severity of pain. They should have a work-
ing knowledge of the World Health Organization pain ladder
and an understanding of the pharmacology and toxicity of the
opiate narcotics and other analgesics. They should be able to
manage cancer pain with the available modalities and recog-
nize when referral for an invasive palliative intervention is
indicated.
4.2.3.5.2.2 Other symptoms. Trainees should be able to palliate
other symptoms (respiratory tract, gastrointestinal tract, neuro-
logic symptoms, cutaneous and mucosal symptoms, anorexia
and cachexia, dehydration). They should know how to handle
end of life symptoms.
4.2.3.5.2.3 Communication. The trainees should be able to
communicate with the patient and his family. They should be
able to break bad news and act adequately in difficult situ-
ations. The trainees should learn to communicate and work
together with other professional health care professionals in a
team (e.g., nurses, social workers, psychologists).
4.2.3.6 Rehabilitation
The trainee should recognize the role of physical therapy, par-
ticularly in the postoperative setting. Trainees should recog-
nize the role of occupational therapy, speech therapy, and
swallowing therapy.
4.3 Management and treatment of individual cancers
Having understood the general principles of treatment, the
trainee should be instructed in the care of individual cancer
types and the unique considerations for each malignant dis-
ease. For each specific disease, the trainee should know the
epidemiology, pathophysiology, genetics, signs and symptoms,
diagnostic work-up, treatment, and follow-up. The trainee
should be able to communicate and discuss these topics with
the patients. For each tumor, specific items may be more
important. They are stated below.
4.3.1 Head and neck cancers
Trainees should know how a proper head and neck examin-
ation is performed. They should know the risk factors for head
and neck cancers and natural histories of the individual pri-
mary tumor sites. Staging of head and neck cancers should be
emphasized as the proper evaluation for therapeutic rec-
ommendations. Panendoscopy is needed for staging. Trainees
should recognize that staging is the basis for selecting surgery
and/or radiation therapy as definitive treatment. They should
be aware of the role of chemotherapy and palliation of
advanced disease. They should recognize when organ preser-
vation may be an option. They should be aware of the long-
term management of these patients and of risks of second
malignancies.
4.3.2 Lung cancer and mesothelioma
The trainees should be aware of the risk factors for developing
lung cancer or mesothelioma.
4.3.2.1 Small-cell lung cancer
Trainees should be familiar with the multimodality approach
to limited-stage disease and the role of chemotherapy in
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patients with advanced disease. They should know the indi-
cations for central nervous system treatment.
4.3.2.2 Non-small-cell lung cancer
Trainees should be familiar with criteria of inoperability and
the surgical and nonsurgical staging of patients with localized
disease. They should be familiar with the value of surgery,
chemotherapy, and radiation therapy in localized disease,
often given as combined modality treatment, and the role of
chemotherapy and/or radiation therapy in the palliation of
advanced disease.
4.3.2.3 Mesothelioma
Trainees should be familiar with the risk factors for mesothe-
lioma, criteria for operability, and the value of chemotherapy.
4.3.3 Gastrointestinal cancers
4.3.3.1 Esophageal cancer
Trainees should appreciate the risk factors for esophageal can-
cer. They should know the indications for endoscopy in the
diagnosis and staging of the disease. Trainees should learn the
indications for nutritional support. They should recognize the
importance of combined modality therapy, as well as the role
of palliative chemotherapy and other supportive care
measures.
4.3.3.2 Gastric cancer
Trainees should recognize unique risk factors for gastric can-
cer. They should understand major surgical approaches to the
disease and recognize the potentially curative role of surgery
and the relative roles of combined modality therapy, as well
as the role of palliative chemotherapy and other supportive
measures.
4.3.3.3 Colon cancer
Trainees should appreciate the importance of surgical staging
and recognize the indications for adjuvant therapies in colon
and rectal cancers and the role of chemotherapy in advanced
metastatic disease. They should recognize heritable types of
colon cancer and the differences in their patterns of spread
and their management. They should understand risk factors
and rationale for screening for colorectal cancer, as well as its
chemoprevention, and should appreciate the role of genetic
testing.
4.3.3.4 Anal cancer
Trainees should recognize the association of human papilloma
virus and anal cancer. They should appreciate the role of com-
bined modality therapy in organ preservation.
4.3.3.5 Hepatobiliary cancers
Trainees should understand the epidemiology and risk factors
for hepatobiliary cancers. They should learn the importance of
alpha-fetoprotein in diagnosis, response assessment, and
screening. They should know the indications for the curative
role of surgery in localized disease and the role of systemic
and intra-arterial chemotherapy.
4.3.3.6 Pancreatic cancer
Trainees should appreciate the risk factors for the development
of pancreatic cancer. They should know the unique genetic
aspects of pancreatic cancer and be familiar with the roles of
endoscopy and molecular diagnosis in pancreatic cancer. They
should know that surgery has a curative role in rare patients
and may provide palliation in others. Also they should recog-
nize the palliative role of chemotherapy in advanced disease.
4.3.4 Genitourinary cancers
4.3.4.1 Renal cell cancer
Trainees should understand the diagnostic aspects of renal cell
cancer and be familiar with paraneoplastic aspects of the dis-
ease. They should appreciate the curative role of surgery in
localized disease and the value of biologic therapies in the
palliation of advanced disease.
4.3.4.2 Urothelial cancers
Trainees should know the risk factors of urothelial cancers,
the differences between localized and invasive disease, and
the propensity for transitional-cell carcinoma to recur. They
should recognize the role of urine cytology and cystoscopy in
the staging and follow-up of patients. They should know the
role of intravesical therapy in the management of superficial
bladder cancer, as well as the role of surgery in early-stage
invasive cancers. They should appreciate the value of com-
bined modality therapy in localized and urothelial disease and
the management of metastatic transitional-cell carcinoma.
4.3.4.3 Penile cancer
Trainees should appreciate the role of human papilloma virus
in the etiology of penile cancers. They should know the poten-
tially curative role of combined modality treatment.
4.3.4.4 Prostate cancer
Trainees should understand the epidemiology and screening of
prostate cancer, including the indications for prostate-specific
antigen in screening and follow-up of patients with prostate
cancer. They should appreciate the importance of histologic
grading. They should recognize the role of observation, sur-
gery, or radiation therapy in the management of early stage
disease, and the application of hormone therapy and
chemotherapy in advanced disease.
4.3.4.5 Germ cell tumors
The trainees should be able to classify patients according to
the International Germ Cell Collaborative Group classification.
Trainees should know the utility of tumor markers in the diag-
nosis, prognosis, and follow-up of patients. They should know
the roles of surgery, radiotherapy, and chemotherapy. They
should know that combination chemotherapy is curative in
advanced disease.
4.3.5 Gynecologic malignancies
4.3.5.1 Ovarian cancer
Trainees should recognize that a predisposition of ovarian
cancer is heritable. They should understand the role of
1609
appropriate surgical procedures in the initial staging and initial
treatment of patients and subsequent systemic treatment. They
should appreciate the indications for chemotherapy in loca-
lized and advanced disease.
4.3.5.2 Uterine cancer
Trainees should recognize the role of hormones and hormonal
therapies in the etiology of endometrial cancers. They should
know the curative role of surgery in early-stage disease and
the value of radiation therapy in the multidisciplinary
approach of more advanced disease. They should also recog-
nize the role of chemotherapy and hormone therapy in the
management of both local and metastatic disease.
4.3.5.3 Cervical cancer
Trainees should recognize unique risk factors for cervical can-
cer. They should recognize that staging is the basis for select-
ing surgery and/or radiation therapy as curative surgery. They
should appreciate the role of chemotherapy in the management
of both local disease combined with radiotherapy and in the
treatment of advanced disease.
4.3.5.4 Vulvar and vaginal cancers
Trainees should know about the induction of clear-cell carci-
noma of the vagina in women whose mothers received
diethylstilbestrol during pregnancy. They should understand
proper surveillance and management of these individuals.
Trainees should recognize the curative role of surgery in
early-stage disease and the need for combination therapy in
advanced disease.
4.3.6 Breast cancer
Trainees should have a working knowledge in the interpret-
ation of a mammogram, ultrasound, and magnetic resonance
imaging scan of the breast. They should recognize the
pathologic and prognostic features that assist in determining
the indications for therapy, including how to manage pre-
neoplastic lesions. They should understand the issues that
affect the choice of primary treatments, including the value
of determination of receptors. They should appreciate the
benefits of hormone therapy and/or chemotherapy in
advanced disease and know the indications for adjuvant
therapy. The role of elective chemotherapy regimens should
be reviewed and understood. They should recognize the
importance of family history and the role for genetic testing
and counselling.
4.3.7 Sarcomas
4.3.7.1 Bone sarcomas
The trainee should recognize the predisposing situation and
condition in the development of primary bone sarcomas. They
should appreciate the pathologic spectrum of these lesions and
know indications and considerations for limb preservation and
adjuvant chemotherapy, and the role of combined modality
therapy for specific tumors.
4.3.7.2 Soft tissue sarcomas
The trainees should know the appropriate surgery for initial
diagnosis and the indications for limb preservation. They
should recognize the roles of chemotherapy, surgery, and
radiation therapy, including the specific medical treatment
available for gastrointestinal tumors.
4.3.8 Skin cancers
4.3.8.1 Melanoma
Trainees should have an appreciation for the risk factors and
varied clinical appearance of primary melanomas and its pre-
cursor lesions, such as dysplastic nevus. They should be able
to recognize skin lesions that are benign from those that are
potentially malignant. They should know the value of tumor
depth and other prognostic factors in assessing prognosis.
They should know what surgical procedure is required in mak-
ing the diagnosis and curative resection. They should be
aware of the indications for biologic therapies in the adjuvant
setting and the potential risks and benefits of chemotherapy
and in advanced disease. Trainees should have a working
knowledge in the primary prevention of melanoma as well as
the recognition and counselling of patients at high risk for
developing melanoma.
4.3.8.2 Basal cell and squamous cell cancers
Trainees should recognize the clinical appearance of these
lesions and appreciate that their occurrence is associated with
sun exposure and may be a long-term complication of cancer
therapy.
4.3.9 Endocrine cancers
Trainees should know the specific diagnostic work-up and
treatment of endocrine cancers. They should know that endo-
crine cancer may be part of a cancer syndrome due to specific
genetic defects. They should know the role of anticancer
drugs in the different endocrine cancers.
4.3.10 Central nervous system malignancies
The trainee should be aware of the roles for surgery, radiation
therapy, and chemotherapy in primary and metastatic disease
involving the central nervous system.
4.3.11 Carcinoma of unknown primary site
The trainee should learn the importance of the tumor histo-
pathology, pathologic analysis, and tumor markers in directing
the work-up. In particular, they should recognize the settings
in which treatment may affect survival, and when it is
palliative.
4.3.12 Hematologic malignancies
4.3.12.1 Leukemia
The trainee should be familiar with all the pathologic
and molecular biologic techniques (cytogenetics, immuno-
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phenotyping, polymerase chain reaction) used in the diagnosis
of leukemia. They should be familiar with the current treat-
ment recommendations and their applications for acute lym-
phoblastic and myeloid leukemia in both the standard adult
population and the elderly.
4.3.12.1.1 Acute leukemias and myelodysplasia:
Trainees should be familiar with the risk factors for develop-
ing leukemia: They should know the French-American-British
classification and its implications for treatment and prognosis.
They should appreciate the potential use of marrow transplan-
tation in patients with leukemia and the value of differen-
tiation therapy.
4.3.12.1.2 Chronic leukemias:
Trainees should be able to distinguish the chronic leukemias
on peripheral-blood smear. Trainees should understand the
current therapeutic approaches in the treatment of the chronic
leukemias in addition to understanding the expectations of
treatment. They should be aware of the indications for marrow
transplantation.
4.3.12.2 Lymphomas
Trainees should be familiar with the Ann Arbor Staging and
World Health Organization classification as well as its
strengths, limitations, and current initiatives to improve upon
the staging classification.
4.3.12.2.1 Hodgkin’s disease:
Trainees should be experienced with the staging of Hodgkin’s
disease and the indications for surgical staging. They should
be familiar with the curative role of radiation therapy in early-
stage disease. They should know the indications for che-
motherapy in stages II, III, and IV. Trainees should be aware
of the long-term complications of treatment and know what is
entailed in the follow-up of patients. They should appreciate
the indications for marrow transplantation in patients with
relapsed or refractory disease.
4.3.12.2.2 Non-Hodgkin’s lymphoma:
Trainees should be aware of the association of lymphomas
with HIV and immunosuppression. They should be familiar
with the Revised European-American Lymphoma classifi-
cation and the International Prognostic Factors. They should
recognize the curative role of chemotherapy and the value of
marrow transplantation in relapsed or refractory disease. They
should understand different types of low-grade lymphomas
and appreciate when treatment is indicated and when obser-
vation is appropriate. They should appreciate the roles of radi-
ation therapy, surgery, and chemotherapy, including
monoclonal antibodies in staging and treatment of intermedi-
ate grade non-Hodgkin’s lymphomas. They should know the
challenge and unique clinical properties of high-grade lym-
phomas and the role for intensive treatment of this subgroup.
4.3.12.2.3 Cutaneous T-cell lymphoma:
Trainees should recognize the clinical appearance of patients
at different stages of the disease. They should be aware of the
value of immunophenotyping in the diagnosis. They should
appreciate the roles of psoralen and ultraviolet A, radiation
therapy, and topical chemotherapy in the initial management
of patients. They should be aware of the palliative roles of
chemotherapy, biologic agents, and radiation therapy in
advanced or refractory disease.
4.3.12.3 Plasma cell dyscrasias
Trainees should know how to distinguish the plasma cell dys-
crasias: monoclonal gammopathy of unknown significance,
Waldenstroms, macroglobulinemia, plasmacytoma, multiple
myeloma, POEMS (polyneuropathy, organomegaly, endocri-
nopathy, monoclonal protein, skin changes), and plasma cell
leukemia. They should know the indications for treatment in
each instance.
4.3.13 AIDS-associated malignancies
The trainee should be familiar with association of central ner-
vous system tumors with immunosuppression and AIDS. The
trainee should recognize the increased incidence of malig-
nancy in the HIV-positive population. They should know the
indications for treatment of those cancers and be aware of the
potential of increased toxicities attributable to concurrent
medical problems. Trainees should know the appropriate pro-
phylaxis and treatment for common opportunistic infections.
5. Psychosocial aspects of cancer
Trainees should know the psychosocial influence of cancer.
They should be aware of available resources and recognize
when intervention is indicated at all stages of disease.
The trainee should know the cultural issues that impact on
the management of disease.
They should appreciate the spiritual conflicts associated
with the diagnosis and treatment of cancer.
Trainees should learn to recognize adaptive and maladap-
tive behavior in coping with disease.
They should recognize acceptable coping mechanisms by
patients and families within the context of the cancer
diagnosis.
Trainees should have an awareness of the issues involved in
end-of-life care.
The trainee should recognize that cancer impacts sexuality
and may result in dysfunction as a result of the disease
process, treatment, or because of psychological effects.
Trainees should be familiar with the indication and uses of
psychotropic drugs.
Trainees should have knowledge of the bereavement
process.
The trainee should have an appreciation of the physicians’
personal coping.
Trainees also should know how to integrate family mem-
bers, pastoral care, nursing support, hospice, and cancer sup-
port groups in the multidisciplinary treatment of patients.
Trainees should be able to communicate with patients and
their family. They should be able to break bad news and act
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adequately in difficult situations. Trainees should learn to
communicate and work together with other professional health
care takers in a team.
6. Patient education
6.1 Genetic counselling
The trainee should be capable of assessing the increased risk
of cancer in the patient and the patient’s family. They should
be aware of the principles for genetic screening and coun-
selling.
6.2 Health maintenance
The trainee should be capable of counselling the patients and
their family about known risk factors for subsequent malig-
nancy: diet, smoking, alcohol, and sun exposure.
6.3 Long-term complications
Trainees should recognize long-term complications of each
treatment modality employed including the following.
6.3.1 Risk of treatment-induced cancers. Acute myeloid
leukemia after chemotherapy, and radiation induced
sarcomas
6.3.2 Endocrine dysfunctions Hypothyroidism after neck
radiation, sterility with chemotherapy
6.4 Chemoprevention measures/clinical trials
6.5 Testing and intervals for follow-up
7. Bioethics, legal, and economic issues
7.1 Informed consent
The trainee should know the requirements for obtaining
informed consent.
7.2 Ethics
The trainee should understand the ethics involved in the
conduct of medical research.
7.3 Legal issues
They should know the legal issues related to anticancer treat-
ment, institution of life support, and withdrawal of life support
systems.
7.4 Cost efficiency
Trainees should appreciate the cost effectiveness of medical
intervention in the management of cancer.
7.5 Conflict of interest
The trainee should be aware of guidelines to define conflict of
interest within professional activities.
7.6 Professional attitude
Trainees must demonstrate professionalism and humanism in
their care of patients and their families.
8. Skills
8.1 Anticancer agent administration
The trainees should have knowledge of how to prescribe and
safely administer anticancer agents. They should be able to
care and access indwelling venous catheters. They should
have knowledge about the handling and disposal of chemo-
therapeutic and biologic agents.
8.2 Bone marrow aspiration, biopsy, and interpretation
Trainees should be able to perform a marrow aspiration and
biopsy. They should have an experience in the interpretation
of marrow aspirations and biopsies. Trainees should have a
fundamental knowledge about marrow interpretation.
8.3 Ommaya reservoir and lumbar puncture
Training must demonstrate an ability to perform a lumbar
puncture and to administer chemotherapy by that route.
The trainee should be able to use a subcutaneous device to
administer medication. He should be able to recognize and
solve complications of such device. Trainees must be capable
of administering chemotherapy through an Ommaya reservoir.
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